Bharat Parenterals Subsidiary Expands Facility to ₹300 Cr for Biologics

Bharat Parenterals Limited announced a strategic enhancement to its wholly-owned subsidiary, Varenyam Biolifesciences Private Limited's, upcoming Savli manufacturing facility. The facility's scope has been upgraded to include biologics and biosimilar CDMO capabilities, in addition to its existing oncology-focused operations. The Phase 1 capital expenditure has been revised to ₹300 crore from the previously planned ₹150 crore. This expansion aims to address gaps in the global biologics supply chain and target markets in the United States, European Union, and SRA Rest-of-World. Regulatory approvals from USFDA, EU-GMP, and ANVISA will be pursued, with an expected completion date of Q2 2028. The company believes this move will strengthen long-term capabilities and capitalize on the evolving biologics and biosimilar CDMO opportunity.